HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New EU Limits On Pyrrolizidine Alkaloids In Dietary Supplements Take Effect

Executive Summary

Following a transitional period of 18 months, maximum levels for pyrrolizidine alkaloids in dietary supplements come into force in the EU from 1 July 2022 for new products placed on the market. Pyrrolizidine alkaloids have been under scrutiny in the EU for over a decade as their consumption has been linked to a number of health issues, including liver damage.

You may also be interested in...



EU CBD Novel Food Applications On Hold As EFSA Considers Health Risks

All European Union CBD novel food applications have been paused by EFSA after its Panel on Nutrition, Novel Foods and Food Allergens raised concerns about the ingredient's safety, pointing in a wide-ranging scientific literature review to a number of data gaps related to bioavailability, liver damage, gastrointestinal issues and possible negative impacts on pregnancy and reproductive health.  

EFSA Considers Vitamin D Max Levels As Part Of VMS Evidence Review

Vitamin D is one of eight micronutrients being reviewed by the European Food Safety Authority in terms of tolerable upper intake levels (ULs).

ASA Finds 'Irresponsible' Weight Loss Ad Difficult To Stomach

Vision Healthcare’s Sensilab pulled Facebook advertisements for its weight loss supplements after UK regulator the Advertising Standards Authority launched an investigation into whether the marketing, which featured slim models, was "irresponsible." 

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel